SSG
KPRX icon

Summit Securities Group’s Kiora Pharmaceuticals KPRX Stock Holding History

Summit Securities Group’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2
Closed -$17K – 295
2016
Q3 		$17K Buy
+2
New +$21.4K 0.01% 148

Other funds holding KPRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Securities Group's KPRX Position: Q4 2016 in Review

Summit Securities Group sold out of Kiora Pharmaceuticals (KPRX) in Q4 2016, closing a stake of 2 shares — an estimated $17K sold.

Summit Securities Group first reported a position in KPRX in Q3 2016 and held it in 1 quarter. The position peaked at $17K in Q3 2016. 5 funds tracked by Wall St. Rank hold KPRX as of Q4 2016.

  • Summit Securities Group reported no remaining Kiora Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Summit Securities Group sold 2 Kiora Pharmaceuticals shares in Q4 2016, an estimated $17K.
  • Summit Securities Group first reported a position in Kiora Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Summit Securities Group's Kiora Pharmaceuticals position peaked at $17K in Q3 2016.
  • 5 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2016.

Based on Summit Securities Group's 13F filing for Q4 2016, filed 25 Jan 2017.